The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...

BioXcel Therapeutics Inc (BTAI) reports significant progress in pivotal trials and improved financial metrics despite revenue challenges.

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning, and welcome to the BioXcel Therapeutics Third ...

Vincent O'Neill; Executive Vice President, Chief of Product Development and Medical Officer; BioXcel Therapeutics Inc Alec Stranahan; Analyst; BofA Securities, Inc.

Research that was carried out by Baylor College of Medicine and Texas Children's Hospital doctors has led to the U.S. Food ...

The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...